ReviewIndian journal of ophthalmology2021
Approach to optic neuritis: An update.
Review in Indian journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Efficacy and Safety of Plasma Exchange and Immunoadsorption for Acute Optic Neuritis in Patients with Demyelinating Diseases: A Systematic Review and Meta-Analysis.Neurosciences (Riyadh, Saudi Arabia) · 2026Pooled it
- Consensus statement for the diagnosis and management of optic neuritis.Indian journal of ophthalmology · 2026Review
- Cup-to-Disc Ratio Is Associated with Disability in Multiple Sclerosis: A Combined OCT and Subjective Visual Vertical Study.Medicina (Kaunas, Lithuania) · 2026Article
- Association of Peripapillary Retinal Nerve Fibre Layer Thickness with Disability and MRI Findings in Multiple Sclerosis: A Retrospective Single-Centre Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Pharmacovigilance analysis of immune checkpoint inhibitor-associated optic nerve toxicity based on the FAERS database.Frontiers in pharmacology · 2026Article
- Optic neuritis and risk of heart failure and atrial fibrillation: A nationwide cohort study.PNAS nexus · 2025Article
- Review
- New optical coherence tomography biomarker for diagnosis of acute optic neuritis in multiple sclerosis.Heliyon · 2025Article
- Management and outcomes of pediatric optic neuritis in a tertiary hospital in Riyadh, Saudi Arabia: a retrospective study.BMC neurology · 2024Article
- Demyelination and neurodegeneration early in experimental autoimmune encephalomyelitis contribute to functional deficits in the anterior visual pathway.Scientific reports · 2024Article
- [Classic presentation of neuromyelitis optica: clinical case and review of the literature].Revista medica del Instituto Mexicano del Seguro Social · 2024Review
- Central nervous system manifestations following vaccination against COVID-19.Brain, behavior, & immunity - health · 2024Review
- A Comparative Review of Typical and Atypical Optic Neuritis: Advancements in Treatments, Diagnostics, and Prognosis.Cureus · 2024Review
- Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges.Journal of clinical medicine · 2023Review
- Acute lymphoblastic leukemia relapse presenting with optic nerve infiltration.SAGE open medical case reports · 2023Article
- Optic Neuritis in Multiple Sclerosis-A Review of Molecular Mechanisms Involved in the Degenerative Process.Current issues in molecular biology · 2022Review
- Article
- Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis.International journal of molecular sciences · 2022Review
- miR-216b-5p Inhibited the Progression of Experimental Optic Neuritis via Downregulating FAS.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Acute Optic Neuritis: An Update on Approach and Management.Journal of ophthalmic & vision researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past few years, there has been remarkable development in the area of optic neuritis. The discovery of new antibodies has improved our understanding of the pathology of the disease. Antiaquaporin4 antibodies and antimyelin oligodendrocytes antibodies are now considered as distinct entities of optic neuritis with their specific clinical presentation, neuroimaging characteristics, treatment options, and course of the disease. Similarly, there has been a substantial change in the treatment of optic neuritis which was earlier limited to steroids and interferons. The development of new immunosuppressant drugs and monoclonal antibodies has reduced the relapses and improved the prognosis of optic neuritis as well as an associated systemic disease. This review article tends to provide an update on the approach and management of optic neuritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.